PDS Biotech Regains Nasdaq Compliance, Resolving Delisting Threat
Summary
PDS Biotechnology announced it has regained compliance with Nasdaq's minimum bid price requirement, eliminating the risk of delisting.
Key Events
-
Regains Nasdaq Compliance
The company received notice from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement, closing the previously disclosed deficiency matter.
-
Removes Delisting Threat
This action removes the immediate threat of delisting from The Nasdaq Capital Market, which had been in effect since February 25, 2026.
Analysis
PDS Biotechnology has successfully resolved the Nasdaq minimum bid price deficiency, which had been a concern since February 2026. This removes the immediate risk of delisting, a critical factor for maintaining investor confidence and market liquidity, especially for a company of this size. The company's stock price is now above the $1.00 threshold.
At the time of this filing, PDSB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.6M. The 52-week trading range was $0.51 to $1.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.